Acute pancreatitis associated with sorafenib.
Since its FDA approval in December 2005, sorafenib (Nexavar) has been in use for the treatment of metastatic renal cell carcinoma. With this increased use have come reports of adverse effects of sorafenib. To the best of the authors' knowledge, they are the first to describe an 80-year-old Asian male with a history of metastatic renal cell carcinoma who developed acute pancreatitis confirmed by computed tomography (CT) one month after taking sorafenib 400 mg orally twice a day. Sorafenib was eventually discontinued, and the pancreatitis resolved. The molecular biologic mechanism causing this side effect is discussed. Patients should be informed of this rare but potentially serious adverse effect before initiation of sorafenib therapy. Early recognition of this complication and complete discontinuation of sorafenib are recommended.
Li
Mingqing
M
Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ, USA.
Srinivas
Sandy
S
D000208:Acute Disease; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary; D004791:Enzyme Inhibitors / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010195:Pancreatitis / Q000139:chemically induced*; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib; D014057:Tomography, X-Ray Computed; D048490:raf Kinases / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D004791:Enzyme Inhibitors; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D048490:raf Kinases